Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 Pipeline Review, H2 2018
Summary
Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 pipeline Target constitutes close to 26 molecules. The latest report Tyrosine Protein Kinase SYK Pipeline Review, H2 2018, outlays comprehensive information on the Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosinephosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAMindependent.
The molecules developed by companies in PreRegistration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8, 3, 11 and 2 respectively. Report covers products from therapy areas Immunology, Oncology, Hematological Disorders, Dermatology, Gastrointestinal, Ophthalmology, Central Nervous System, Respiratory, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Rheumatoid Arthritis, Diffuse Large BCell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Idiopathic Thrombocytopenic Purpura Immune Thrombocytopenic Purpura, Waldenstrom Macroglobulinemia Lymphoplasmacytic Lymphoma, Atopic Dermatitis Atopic Eczema, Autoimmune Disorders, Ulcerative Colitis, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Allergic Conjunctivitis, Asthma, BCell Chronic Lymphocytic Leukemia, Blood Cancer, Marginal Zone Bcell Lymphoma, Peripheral TCell Lymphomas PTCL, Refractory Chronic Lymphocytic Leukemia CLL, Relapsed Chronic Lymphocytic Leukemia CLL, Acquired Autoimmune Hemolytic Anemia, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Allergies, Alopecia, Alzheimer's Disease, Arthritis, BCell NonHodgkin Lymphoma, Bladder Cancer, Chronic Cutaneous Lupus Erythematosus CCLE / Discoid Lupus Erythematosus DLE, Chronic Lymphocytic Leukemia CLL, Colon Cancer, Cutaneous Lupus Erythematosus, Cutaneous TCell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastric Cancer, Glomerulonephritis, Hand Dermatitis, Keratoconjunctivitis Sicca Dry Eye, Kidney Transplant Rejection, Lupus Erythematosus, Lupus Nephritis, Metastatic Breast Cancer, Multiple Myeloma Kahler Disease, Multiple Sclerosis, NonHodgkin Lymphoma, NonSmall Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, PostTransplant Lymphoproliferative Disorder, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Sicca Syndrome Sjogren, Subacute Cutaneous Lupus Erythematosus SCLE, Systemic Lupus Erythematosus and Vitiligo.
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2
The report reviews Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 targeted therapeutics and enlists all their major and minor projects
The report assesses Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope